Mirum reports Q3 sales of $185.7M, ups guidance
Mirum released Q3 2026 financial results and increased net product sales guidance to $715M-$720M. Additionally, the company received FDA approval for ATEBRIOZ and announced positive trial data for its late-stage pipeline.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed